Regulatory Q&A Forum

When utilizing a multiple predicate (or "split predicate") strategy in a 510(k) submission, where a new device combines key features from two or more different legally marketed devices, what is a comp...

After receiving an FDA Form 483, a medical device manufacturer faces a critical 15-business-day window to submit a formal response. How can a firm strategically structure this period to develop a comp...

For medical device sponsors, a common point of confusion is the discrepancy between the FDA's 90-day 510(k) review goal and the actual "total time to clearance." While the agency aims for 90 FDA Days,...

How can medical device sponsors develop a robust internal checklist to proactively mitigate the most common administrative and content-related deficiencies that lead to a Refuse to Accept (RTA) hold o...

When preparing a 510(k) submission for a device incorporating novel features, such as a diagnostic catheter with a new sensor technology, sponsors must often select a predicate from a pool of imperfec...

When preparing a 510(k) for a Class II device, such as a diagnostic ultrasound system, how does a sponsor systematically distinguish between, identify, and document conformance with both General and S...

Beyond creating a basic checklist of FDA’s General Controls, what practical, auditable framework can a medical device manufacturer implement to ensure robust, ongoing compliance? For instance: 1. Es...

Beyond simple administrative oversights like an improperly formatted eCopy or a missing user fee form, what are the most critical, yet frequently overlooked, technical and content-related deficiencies...

When preparing a 510(k) submission for a device with different technological characteristics (DTCs) compared to its predicate, what is a robust framework for establishing substantial equivalence (SE)?...

When a medical device manufacturer identifies a product classification regulation for their Class II device that states it is "exempt from the premarket notification procedures in subpart E of part 80...

I'm evaluating multiple EU Responsible Person providers and want to make sure I ask the right questions. What should I look for, what questions should I ask, and what are the red flags to avoid?

I'm planning to sell my cosmetic products in both the EU and the UK. Do I need separate Responsible Persons for each market, or can my EU RP also cover the UK?

I have multiple cosmetic products and many variants (different shades, fragrances, etc.). Can one Responsible Person handle all of them, or do I need separate RPs for each product or variant?

I'm ready to engage an EU Responsible Person provider but want to be prepared. What documentation, information, and materials should I have ready to make the process smooth and efficient?

I'm concerned about what happens if a consumer reports a serious adverse reaction to my cosmetic product. What are the reporting requirements, who must be notified, and what are the timelines?

My cosmetic product is already on the EU market. What changes or events require me to update my CPNP notification, PIF, or other compliance documentation? When must updates be submitted?

I'm a brand owner who private-labels cosmetic products manufactured by a third party. If I sell products under my own brand name, do I automatically become the Responsible Person, or can the manufactu...

I'm confused about the different roles in the EU cosmetics supply chain. What's the difference between the Responsible Person, importer, and distributor, and can the same company fulfill multiple role...

I'm considering using a virtual office or mail forwarding service for my EU Responsible Person address. Is this allowed under EU cosmetics regulations, and what are the practical considerations?

I'm preparing labels for my cosmetic products to sell in the EU. What are all the mandatory labeling requirements, including Responsible Person information, ingredients, warnings, and other required e...